Presidency event - Poland. Research and Innovations for health and quality of life - how to exploit the exponential growth of possibilities

This action will cover the organisation of an event by the Polish Presidency aimed at highlighting the critical role of research and innovation in harnessing technological advancements to enhance human health and well-being. It will emphasise the immense potential of merging diverse technologies to address complex healthcare challenges and improve the quality of life for individuals in Europe and globally.

The innovation and development of health products and services involve a complex ecosystem of interconnected sectors working together to translate scientific discoveries into tangible solutions for patients and healthcare providers. To that end, the conference will bring together stakeholders from sectors broadly categorised into four main areas:

• Research and Development include science and academia, government R&D institutions, and pharma-biotech companies that engage in fundamental and applied research, leading to discoveries in biology, medicine, and healthcare technology.
• Manufacturing and Supply Chain encompass pharmaceutical manufacturers, medical device companies, healthcare IT providers, and distributors – i.e. companies which ensure that the products and services developed by R&D are manufactured to high-quality standards, transported efficiently, and made accessible to patients and healthcare providers.
• The Regulatory and Reimbursement includes government agencies, insurance companies, and healthcare payers, who ensure the safety, efficacy, and accessibility of health-related products and services.
• The Support and Advocacy include non-profit organisations, patient groups and other public and private organisations and programs representing the interests of patients and providing support and education to those affected by specific diseases or conditions.

The effective functioning of this complex ecosystem requires strong collaboration and communication among policymakers and stakeholders in science, innovation and public health as well as the European Commission. Only by working together will it be possible to create a future where we use technology to improve the health and well-being of everyone.

The conference will create a forum for:

• networking and exchanging knowledge to confront the expectations, factual impact, and challenges,
• informing regulatory frameworks, addressing potential barriers and collaborative strategies to overcome these,
• facilitating discussions on market access considerations involving regulatory, industry and HTA stakeholders,
• sharing best practices and potential for opportunities for scaling up what works.

As a result, the conference will develop the systemic perspective of needs and recommend future directions of actions, collaborations, and synergies.

Award criteria:

The criteria are described in General Annex D. The following exceptions apply: The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.

Procedure:

The evaluation committee will be composed fully by representatives of EU institutions.

Legal and financial set-up of the Grant Agreements:

The funding rate will be 100%.

Subcontracting is not restricted to a limited part of the action.